Скачать
COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-m...
Автор: ecancer
Загружено: 2018-10-29
Просмотров: 645
Описание:
Prof Dirk Schadendorf speaks with ecancer at ESMO 2018 in Munich about the outcomes from the COLUMBUS trial which looked into the use of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma.
Prof Schadendorf explains that for patients receiving encorafenib plus binimetinib there was a median overall survival of 33 months, which was the highest of all the combinations so far.
He also points out the value of the direct comparison between the two B-RAF inhibitors, with encorafenib shown to be clearly superior.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
